Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
MyMD Pharmaceuticals to host business news update conference call » 15:55
05/17/21
05/17
15:55
05/17/21
15:55
MYMD

MyMD Pharmaceuticals

$3.50 /

+0.1 (+2.94%)

Management provide an…

Management provide an update on its clinical and drug development plan on a business news update conference call to be held on May 17 at 4:15 pm. Webcast Link

ShowHide Related Items >><<
MYMD MyMD Pharmaceuticals
$3.50 /

+0.1 (+2.94%)

MYMD MyMD Pharmaceuticals
$3.50 /

+0.1 (+2.94%)

Conference/Events
MyMD Pharmaceuticals to host business news update conference call » 04:55
05/17/21
05/17
04:55
05/17/21
04:55
MYMD

MyMD Pharmaceuticals

$3.40 /

-0.25 (-6.85%)

Management provide an…

Management provide an update on its clinical and drug development plan on a business news update conference call to be held on May 17 at 4:15 pm. Webcast Link

ShowHide Related Items >><<
MYMD MyMD Pharmaceuticals
$3.40 /

-0.25 (-6.85%)

MYMD MyMD Pharmaceuticals
$3.40 /

-0.25 (-6.85%)

Conference/Events
MyMD Pharmaceuticals to host business news update conference call » 13:21
05/16/21
05/16
13:21
05/16/21
13:21
MYMD

MyMD Pharmaceuticals

$3.40 /

-0.25 (-6.85%)

Management provide an…

Management provide an update on its clinical and drug development plan on a business news update conference call to be held on May 17 at 4:15 pm. Webcast Link

ShowHide Related Items >><<
MYMD MyMD Pharmaceuticals
$3.40 /

-0.25 (-6.85%)

MYMD MyMD Pharmaceuticals
$3.40 /

-0.25 (-6.85%)

Options
new option listings and one option delisting on May 5th » 08:30
05/05/21
05/05
08:30
05/05/21
08:30
AIQ

Alliance HealthCare

$28.51 /

-0.66 (-2.26%)

, ASEA

Aegean Sea

$14.66 /

-0.185 (-1.25%)

, BTX

Brooklyn ImmunoTherapeutics

$54.73 /

-21.32 (-28.03%)

, CIGI

Colliers International

$115.70 /

+6.09 (+5.56%)

, DOOO

BRP Inc.

$90.90 /

-1.6 (-1.73%)

, EDR

Endeavor Group

$29.99 /

-0.785 (-2.55%)

, ELDN

Eledon Pharmaceuticals

$9.85 /

-0.05 (-0.51%)

, FLUX

Flux Power

$10.44 /

-0.505 (-4.61%)

, FSV

FirstService

$159.97 /

-2.31 (-1.42%)

, GWRS

Global Water Resources

$16.50 /

-0.67 (-3.90%)

, MYMD

MyMD Pharmaceuticals

$4.20 /

-0.01 (-0.24%)

, NEBC

Nebula Caravel Acquisition

$9.90 /

+ (+0.00%)

, SLGL

Sol-Gel Technologies

$10.51 /

-0.19 (-1.78%)

, TARA

Protara Therapeutics

$10.43 /

-0.76 (-6.79%)

, VRCA

Verrica Pharmaceuticals

$12.27 /

-0.08 (-0.65%)

New option listings for…

New option listings for May 5th include Global X Funds Global X Future Analytics Tech ETF (AIQ), Global X SuperDividend Alternatives (ALTY), Global X Southeast Asia (ASEA), Aspirational Consumer Lifestyle Corp (Class A Stock) (ASPL), Brooklyn ImmunoTherapeutics Inc (BTX), Global X MSCI China Information Technology ETF (CHIK), Colliers International (CIGI), BRP Inc (DOOO), Endeavor Group Holdings Inc (Class A Stock) (EDR), Eledon Pharmaceuticals Inc (ELDN), Fidelity Momentum Factor ETF (FDMO), Fidelity Dividend ETF for Rising Rates (FDRR), Fidelity Core Dividend ETF (FDVV), Fidelity International High Dividend ETF (FIDI), Flux Power Holdings Inc (FLUX), Fidelity Quality Factor ETF (FQAL), Fidelity Small Mid Multifactor ETF (FSMD), FirstService (FSV), Fidelity Value Factor ETF (FVAL), Global Water Resources (GWRS), Global X Thematic Growth ETF (GXTG), Direxion Daily S&P 500 High Beta Bull 3x Shares (HIBL), Global X Conscious Companies (KRMA), Global X Millennials Thematic (MILN), MyMD Pharmaceuticals Inc (MYMD), Nebula Caravel Acquisition Corporation (Class A Stock) (NEBC), Fidelity Nasdaq Composite Index (ONEQ), First Trust Nasdaq Artificial Intelligence and Robotics (ROBT), Global X SuperDividend Emerging Markets ETF (SDEM), Sol Gel Technologies Ltd (SLGL), SVF Investment Corporation (Class A Stock) (SVFA), Protara Therapeutics Inc (TARA), Verrica Parmaceuticals Inc (VRCA), Direxion Daily Consumer Discretionary Bull 3x Shares (WANT), Direxion Daily Dow Jones Internet Bull 3x Shares (WEBL), and Global X S&P 500 Covered Call ETF (XYLD). Option delistings effective May 5th include Valaris Plc (VALPQ).

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

MYMD MyMD Pharmaceuticals
$4.20 /

-0.01 (-0.24%)

GWRS Global Water Resources
$16.50 /

-0.67 (-3.90%)

FSV FirstService
$159.97 /

-2.31 (-1.42%)

FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

AIQ Alliance HealthCare
$28.51 /

-0.66 (-2.26%)

ASEA Aegean Sea
$14.66 /

-0.185 (-1.25%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

02/16/21 TD Securities
Colliers International price target raised to $125 from $100 at TD Securities
02/16/21 RBC Capital
Colliers International price target raised to $126 from $96 at RBC Capital
02/16/21 RBC Capital
Colliers International price target raised to $126 from $96 at RBC Capital
01/25/21
Fly Intel: Top five analyst initiations
DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

04/26/21 Citi
BRP Inc. initiated with a Buy at Citi
04/06/21 Stifel
BRP Inc. downgraded to Hold from Buy at Stifel
03/29/21 Desjardins
BRP Inc. price target raised to C$131 from C$107 at Desjardins
03/26/21 CIBC
BRP Inc. price target raised to C$117 from C$100 at CIBC
EDR Endeavor Group
$29.99 /

-0.785 (-2.55%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 Cantor Fitzgerald
Eledon Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
03/22/21 Cantor Fitzgerald
Eledon Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
02/08/21 SVB Leerink
SVB Leerink bullish on Eledon Pharmaceuticals, initiates with an Outperform
FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21
Flux Power initiated with a Buy at Maxim
10/12/20 Roth Capital
Flux Power initiated with a Buy at Roth Capital
FSV FirstService
$159.97 /

-2.31 (-1.42%)

04/28/21 Raymond James
Raymond James downgrades FirstService to Market Perform on 'healthy valuation'
04/28/21 Raymond James
FirstService downgraded to Market Perform from Outperform at Raymond James
04/28/21
Fly Intel: Top five analyst downgrades
04/28/21 TD Securities
FirstService downgraded to Hold from Buy at TD Securities
GWRS Global Water Resources
$16.50 /

-0.67 (-3.90%)

02/25/21 Roth Capital
Global Water Resources price target raised to $19 from $12.50 at Roth Capital
MYMD MyMD Pharmaceuticals
$4.20 /

-0.01 (-0.24%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

04/09/21
Fly Intel: Top five analyst initiations
04/09/21 Tigress Financial
Nebula Caravel Acquisition initiated with a Buy at Tigress Financial
03/19/21
Fly Intel: Top five analyst initiations
03/19/21 DA Davidson
Rover initiated with a Buy at DA Davidson amid COVID-related tailwinds
SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

FSV FirstService
$159.97 /

-2.31 (-1.42%)

FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

  • 29
    Apr
  • 23
    Mar
  • 22
    Sep
DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

EDR Endeavor Group
$29.99 /

-0.785 (-2.55%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

Hot Stocks
MyMD Pharmaceuticals gets issuance of allowance from USPTO for Supera-CBD » 09:28
04/22/21
04/22
09:28
04/22/21
09:28
MYMD

MyMD Pharmaceuticals

$4.56 /

-0.35 (-7.13%)

MyMD Pharmaceuticals…

MyMD Pharmaceuticals announced that the United States Patent and Trademark Office, USPTO, issued a Notice of Allowance for application no. 16/612,472, entitled "Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders." Supera-CBD is well positioned to address key unmet needs in epilepsy and chronic pain. The allowed claims cover the new molecular entity Supera-CBD as well as pharmaceutical compositions containing the compound. The USPTO found the claims patentable based in part on the compound's unexpectedly improved activity and selectivity toward inhibiting cannabinoid receptor type 2 , a key therapeutic target for neuroinflammatory and neurodegenerative diseases. "The issuance of this Notice of Allowance for our molecule, Supera-CBD, continues to demonstrate our steadfast commitment to moving forward with and protecting our entire product portfolio," said Adam Kaplin, M.D., Chief Scientific Officer of MyMD. "We are thrilled that Supera-CBD has shown strong promise in treating neuroinflammatory and neurodegenerative diseases, and is expected to be a major focus for our company as we move forward."

ShowHide Related Items >><<
MYMD MyMD Pharmaceuticals
$4.56 /

-0.35 (-7.13%)

Hot Stocks
Akers Biosciences announces stockholder approval for MyMD merger » 12:32
04/16/21
04/16
12:32
04/16/21
12:32
AKER

Akers Biosciences

$2.56 /

-0.14 (-5.19%)

, MYMD

MyMD Pharmaceuticals

/

+

Akers Biosciences and…

Akers Biosciences and MyMD Pharmaceuticals announced that at Akers' special meeting of stockholders held on April 15, 2021, Akers obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Akers and MYMD. MYMD previously obtained a sufficient number of written consents from its stockholders to consummate the merger. Upon closing, the combined company will be named MyMD Pharmaceuticals, Inc. and will remain listed on the Nasdaq under the new ticker symbol "MYMD," beginning April 19, 2021. The company intends to focus on developing and commercializing novel immunotherapy pipeline assets, including MYMD-1, a first-in-class drug being developed to treat autoimmune and age-related diseases, including extending the human lifespan.

ShowHide Related Items >><<
AKER Akers Biosciences
$2.56 /

-0.14 (-5.19%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.